What is Fibronostics?
Fibronostics operates as a sophisticated global diagnostics enterprise, specializing in the development of non-invasive, AI-driven diagnostic solutions. The company focuses on the screening, progression, and prognosis of complex chronic conditions, with a particular emphasis on liver and kidney disease. By integrating advanced machine learning algorithms into clinical workflows, Fibronostics provides healthcare providers with actionable insights that improve patient outcomes and streamline diagnostic processes.
As a portfolio company of SPRIM, Fibronostics benefits from a deep-rooted pedigree in worldwide health innovation, research, and consulting. This strategic alignment allows the company to bridge the gap between complex medical data and practical clinical application. With operations spanning Singapore and New York, the firm maintains a robust international presence, enabling it to navigate the regulatory and operational nuances of multiple global markets effectively.
How much funding has Fibronostics raised?
Fibronostics has raised a total of $14.5M across 2 funding rounds:
Series A
$8M
Unspecified
$6.5M
Series A (2020): $8M with participation from AT Capital and Elev8.vc
Unspecified (2022): $6.5M, investors not publicly disclosed
Key Investors in Fibronostics
AT Capital
AT Capital Group is a prominent family office that specializes in actively managed businesses and passive financial investments, utilizing its own funds for investments. The company focuses on sustainable businesses, aiming to create value for all stakeholders while maintaining full control over investment choices and durations.
Elev8.vc
Elev8.vc is a venture capital firm that focuses on early-stage technology investments, providing strategic guidance and capital to companies poised for significant market disruption.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Fibronostics?
Looking ahead, the recent capital injection is expected to accelerate the deployment of Fibronostics' diagnostic suite into new territories and clinical segments. The company is well-positioned to leverage its AI-centric infrastructure to address the growing demand for non-invasive screening tools in the management of chronic diseases. Strategic priorities likely include the expansion of its R&D pipeline, the enhancement of its proprietary algorithm accuracy, and the deepening of its commercial partnerships in key international markets.
Furthermore, the firm's focus on sustainable growth and innovation suggests a continued commitment to scaling its operations while maintaining the high standards of clinical efficacy that define its brand. As the diagnostic sector continues to evolve toward precision medicine, Fibronostics remains at the forefront, utilizing its financial resources to drive the next generation of health-tech advancements.
